Lomotil is a prescription antidiarrheal that combines diphenoxylate hydrochloride with a small amount of atropine sulfate. Because diphenoxylate is chemically an opioid, people who take Lomotil sometimes worry it will trigger a positive result on a workplace or clinical urine drug test. The short answer is that a standard opiate immunoassay, the kind used in most drug test cups and dip cards, is built around morphine and codeine and does not reliably pick up diphenoxylate. This article explains why, what the laboratory process actually looks for, and what an employee with a legitimate prescription should do if a question comes up during review.
What is in Lomotil
According to the prescribing information on file with the FDA, Lomotil tablets and oral liquid contain diphenoxylate hydrochloride 2.5 mg together with atropine sulfate 0.025 mg per dose unit. Diphenoxylate is the active ingredient that slows intestinal motility to treat diarrhea. Atropine is included at a subtherapeutic dose specifically to discourage misuse, since taking large amounts of the combination product causes unpleasant anticholinergic effects such as dry mouth, blurred vision, and a rapid heartbeat. The full labeling, including the drug's chemical description and warnings, is published on the National Library of Medicine's DailyMed label for Lomotil.
Diphenoxylate itself belongs to the phenylpiperidine family of synthetic opioids, the same chemical family as meperidine. It is not derived from morphine or codeine and it does not share their core structure. That distinction matters later when we look at how immunoassay antibodies are designed to detect certain opioid shapes and not others.
Why Lomotil is a controlled substance either way
Diphenoxylate on its own, in bulk or unformulated form, is controlled under Schedule II. When it is combined with atropine sulfate at the ratio used in Lomotil, the Drug Enforcement Administration places the finished combination product in Schedule V, its lowest control schedule, because the atropine component reduces the likelihood of misuse at normal doses. This specific listing for diphenoxylate preparations appears in the DEA's own schedules, which can be verified on the eCFR text of 21 CFR 1308.14 and in the DEA's published controlled substances orange book. The practical point for employers and employees is that Lomotil is a legitimate prescription medication, not an over the counter remedy, and a person taking it should have documentation from a prescribing clinician on file in case any question comes up during a review.
How the standard opiate screen is built
Most workplace and point of care urine drug test cups and dip cards use an immunoassay, a chemistry method built on antibodies that bind to a target molecule's shape. The opiate immunoassay used across the federally regulated workplace testing framework is designed and calibrated around morphine and codeine. The federal rule that governs which drugs a laboratory must screen for in regulated, safety sensitive testing, and how the opiate category is defined, is published at 49 CFR 40.85, with the specific cutoff concentrations the lab applies at the immunoassay and confirmation stages listed at 49 CFR 40.87. Some expanded panels add antibodies tuned for semi synthetic opioids such as oxycodone, hydrocodone, and hydromorphone, which share more structural similarity to morphine than diphenoxylate does.
Diphenoxylate's phenylpiperidine structure does not match the morphine type target that these antibodies are built to recognize. Published cross reactivity data specific to diphenoxylate against standard opiate immunoassays is limited, and manufacturers do not list it as a compound their opiate strips are designed to flag. That means there is no credible, published basis to expect a standard immunoassay cup or dip card to turn positive from a normal therapeutic dose of Lomotil on the opiate panel, and there is no published evidence tying it to a false positive on the amphetamine, cocaine, cannabinoid (THC), phencyclidine (PCP), benzodiazepine, or barbiturate panels either, since those immunoassays target entirely unrelated drug classes.
When a laboratory can actually find it
A cross reactivity accident on an immunoassay is a different thing from a laboratory deliberately testing for a named compound. If a clinical, forensic, or pain management monitoring program specifically wants to know whether diphenoxylate or its metabolite difenoxin is present, a laboratory can run a targeted analysis using gas chromatography mass spectrometry (GC/MS) or liquid chromatography tandem mass spectrometry (LC/MS), the same confirmation technology used to verify any presumptive immunoassay result. That is an intentional, analyte specific test ordered because someone asked for it, not something a standard opiate immunoassay cup will stumble into on its own. Anyone managing a monitoring program who needs this level of detail should ask the laboratory directly which analytes its menu covers, since not every panel includes every compound by default.
What to do if a result needs review
In a regulated or employer administered testing program, a nonnegative screening result does not become a final reportable result on its own. A certifying scientist confirms any immunoassay positive with mass spectrometry, and a medical review officer (MRO), a licensed physician trained in this review process, contacts the individual to ask about current prescriptions before any result is reported to an employer. An employee taking Lomotil under a valid prescription should keep that prescription information available and tell the MRO about it during that contact. The federal workplace testing rule describes this verification step as part of the overall program; a general overview of how these federal programs are structured is published by the Substance Abuse and Mental Health Services Administration, which maintains the Mandatory Guidelines referenced throughout this process.
Antidiarrheal medications and opiate panel notes
| Medication | Drug class | Prescription status | Opiate immunoassay note |
|---|---|---|---|
| Diphenoxylate with atropine (Lomotil) | Synthetic opioid, phenylpiperidine type | Prescription, Schedule V combination | Not a morphine or codeine type structure; standard opiate immunoassays do not reliably detect it; a targeted LC/MS or GC/MS test can if specifically ordered |
| Loperamide (Imodium) | Peripherally acting opioid receptor agonist | Over the counter and prescription strength | Does not meaningfully cross the blood brain barrier at normal doses and is generally not expected to trigger standard opiate screens; case reports involve substantial misuse doses, not typical use |
| Bismuth subsalicylate (Pepto-Bismol, Kaopectate) | Antidiarrheal and antacid, salicylate compound | Over the counter | Not an opioid; no credible cross reactivity evidence on opiate, amphetamine, or cannabinoid panels |
Readers can see how a related opioid receptor agent is evaluated in more depth in American Screening Corporation's article on whether loperamide shows up on a drug test, and in the discussion of opioid antagonist treatment testing in whether naltrexone shows up on a drug test.
Guidance for employers and testing programs
Employers designing a drug free workplace program should treat any nonnegative opiate screen the same way regardless of what medication an employee eventually reports, by routing it through confirmation testing and MRO review rather than making an employment decision off a presumptive immunoassay result. Programs that need a documented chain of custody and lab confirmed results, rather than a point of care read alone, should use cups or dip cards that are designed to be sent to a certified laboratory when a result is nonnegative. American Screening Corporation's drug test cup collection includes configurations built for exactly that workflow.
Frequently asked questions
Does Lomotil show up on a standard opiate drug test?
Not reliably. Standard opiate immunoassays are built around morphine and codeine, and diphenoxylate, the active ingredient in Lomotil, has a different chemical structure. There is no credible published evidence that typical Lomotil doses cause a positive opiate screen on a standard immunoassay.
Is diphenoxylate the same thing as an opioid pain medication?
Diphenoxylate is chemically a synthetic opioid related to meperidine, but it is formulated and prescribed as an antidiarrheal, not a pain reliever, and is combined with atropine specifically to limit misuse potential.
Can a laboratory specifically test for diphenoxylate?
Yes. A laboratory can run a targeted GC/MS or LC/MS analysis for diphenoxylate and its metabolite difenoxin if that specific compound is requested, separate from a standard immunoassay opiate panel.
What should someone do if they take Lomotil and are asked to test?
Keep the prescription information available and report it to the medical review officer if contacted about any nonnegative result. This is a normal part of the verification process and is not a medical or legal determination on its own.
Is Lomotil a controlled substance?
Yes. The diphenoxylate and atropine combination is listed in Schedule V under DEA scheduling because of the added atropine, while diphenoxylate alone in unformulated form is controlled at a higher schedule.
Does loperamide (Imodium) behave the same way as Lomotil on a drug test?
Loperamide is also an opioid receptor agonist but it is designed to act only in the gut and does not meaningfully reach the brain at normal doses, so it is generally not expected to trigger standard opiate screens either, though it works through a different mechanism than diphenoxylate.
This article is general information about drug test screening science and is not legal or medical advice. Anyone with questions about a specific test result or medication should speak with a qualified medical review officer or healthcare provider.
